Current Corporate Collaborators

Collaborator	Program	Disease
Genentech (vismodegib)	Hedgehog Pathway Inhibitor	Cancer
Debiopharm SA (Debio 0932)	Debio 0932 (Hsp90 inhibitor; formerly CUDC-305)	Cancer

Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.

The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program.  In September 2011, Genentech completed an NDA submission with the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma.  In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.

Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase I clinical testing.